Introduction {#s1}
============

The *ATP-binding cassette subfamily B member 1* (*ABCB1*) gene, a *multidrug resistance protein 1* (*MDR1*) gene, is located on the chromosomal region 7q21.1 and encodes p-glycoprotein (P-gp), which plays an important role in drug bioavailability and response to drugs. P-gp is a 1280-amino acid transporter and serves as a genetically polymorphic efflux transporter that removes foreign substances from cells. This protein is expressed in the blood--brain barrier and protects the brain from drugs or neurotoxic substances, such as glucocorticoids and amyloid beta ([@B2]).

After treatment with regular doses of antidepressants, several patients with major depressive disorder (MDD) fail to obtain satisfactory therapeutic effects, and some patients even incur serious side effects. Among patients with MDD treated with a single antidepressant medication, only 50% of patients received adequate clinical response, and 30% of patients achieved recovery. There was a delayed response to symptom relief, ranging from 4 to 8 weeks. During this period, the risk of suicide increased significantly, whereas another 10% of the patients were ineffective for any kind of antidepressant medication ([@B18]). *ABCB1* gene polymorphisms affect the ability of drugs to pass through the blood--brain barrier into the central nervous system, leading to inadequate drug concentrations in the brain ([@B17]). *ABCB1* gene polymorphisms can predict the effect of antidepressant drugs that are *MDR1* substrates ([@B7]; [@B11]).

Some drugs have been identified as substrates of P-gp. These drugs include nortriptyline, imipramine, escitalopram, amitriptyline, paroxetine, venlafaxine, and citalopram; and those with non-*ABCB1* substrates include bupropion, mirtazapine, and fluoxetine ([@B7]). The *ABCB1* gene has single-nucleotide polymorphisms (SNPs) in the encoding regions. Variants such as C3435T (rs1045642), G2677T/A (rs2032582), and rs2032583 are the most commonly studied. [@B1] reported that *ABCB1* gene knockout mice possessed insufficient P-gp, leading to high drug concentrations in the blood and weak ability to eliminate drugs. The plasma concentrations of drugs in mice without the *ABCB1* gene were fivefold higher and seven- to 36-fold higher in the cerebrospinal fluid ([@B1]).The concentrations of citalopram, venlafaxine, and d-venlafaxine in the brain of mutant mice were 3.0, 1.7, and 4.1 times higher than those in their wild-type littermates ([@B17]). *In vivo* studies indicated that mdr1 ab (−/−) mutant mice possessed higher cerebral concentrations of paroxetine compared with those of mdr1ab (+/+) control mice. This finding suggests that P-gp could prevent paroxetine from entering into the brain ([@B14]). Patients with the CC genotype of SNP rs2232583 in the *ABCB1* gene exhibited a higher response rate than that of patients with the TT genotype after 4 weeks of antidepressant treatment. However, in the non-P-gp substrate mirtazapine group, no difference in genotype was observed between remission and nonremission groups ([@B13]). A similar result was also found by [@B11]. Moreover, Dong et al. reported that *ABCB1* gene polymorphisms rs4728697, rs2032583, and rs58898486 were associated with depression therapeutic response, and rs17064 was related to the curative effect of desipramine ([@B3]). *ABCB1* haplotypes and SNPs rs1045642, rs2032582, and rs2032583 affect responses to antidepressant treatment ([@B6]; [@B10]; [@B5]; [@B12]; [@B2]).

A total of 292 Chinese patients with MDD and 208 unrelated control individuals from a local Chinese Han population were studied. There are few studies on the relationship between gene polymorphism of *ABCB1* and depression in the Chinese Han population; only a team of Taiwan scholars studied the relationship between the efficacy of escitalopram and gene polymorphism of *ABCB1* in patients with depression ([@B5]). The purpose of this study was to further understand the relationship between the two in the Chinese Han population and to provide a theoretical basis for individualized treatment.

Materials and Methods {#s2}
=====================

Subjects {#s2_1}
--------

A total of 292 patients with MDD and 208 healthy controls were included in this study. All participants were biologically unrelated and of Chinese Han ethnicity. The patients were diagnosed as having MDD as defined in the Axis I of the *Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision* (DSM-IV-TR) and obtained scores ≥18 by the 17-item Hamilton Depression (HAM-D17) Rating Scale. A consensus diagnosis by at least two psychiatrists was made for each patient according to the DSM-IV criteria. Patients were not eligible to participate in the study if they have any other mental disorder according to DSM-IV-TR Axis I criteria, had major physical and neurological illnesses and sequelae of serious illness, or serious suicide attempts and behavior. Patients were also excluded if they had used electroconvulsive therapy or antipsychotic drugs with long-lasting effects within the last 6 months or any antipsychotic drugs within the last 4 weeks. The mean ages ± standard deviations of the patients and controls were 30.89 ± 10.92 years and 31.71 ± 8.25 years, respectively. Among the 292 patients with MDD, 71.6% had a single episode and 28.4% had recurrent episodes. The study protocol was approved by the Medical Ethics Committee of Second Xiangya Hospital, Central South University. Written informed consent was obtained from each patient after the study was explained.

Study Design {#s2_2}
------------

Eligible patients were treated with one of the five antidepressants (escitalopram, paroxetine, sertraline, duloxetine, and venlafaxine) for 6 weeks. All patients affirmed a regular dose intake of antidepressant drug per day during the study. The primary efficacy measurement was the change in the HAM-D17 total score from baseline until the end of the study period. Patients were evaluated at screening, baseline, and on the first, second, fourth, and sixth weeks of treatment. Response was defined as changes in the HAM-D17 total score of ≥50%.

Sample Collection and DNA Extraction {#s2_3}
------------------------------------

Peripheral blood samples were collected from ethylene diamine tetraacetic acid (EDTA)-containing tubes following the standard venipuncture technique. Genomic DNA was extracted from whole blood according to standard procedures. In this study, we selected SNPs by the following three methods: literature reviewing, searching for Tag-SNP, and searching for functional variant sites by FAST SNP. Finally, we investigated the following six SNPs of the *ABCB1* gene: SNP1 (rs1045642) in exon 27, SNP2 (rs2032583) in intron 22, SNP3 (rs2032582) in exon 22, SNP4 (rs2235040) in intron boundary exon 21, SNP5 (rs1128503) in exon 13, and SNP6 (rs2235015) in intron 5 of the *ABCB1* gene. All genotyping experiments were carried out by Shanghai BioWing Applied Biotechnology Company (<http://www.biowing.com.cn>). The AxyPrep Blood Genomic DNA Kit was used for extraction, and the ligase detection reaction (LDR) was used to detect the six SNPs. The LDR was performed in 30 cycles at 95°C for 2 min, 94°C for 15 s, and 50°C for 25 s. Target DNA sequences were amplified using a multiplex polymerase chain reaction method. The fluorescent products of the LDR were differentiated using a 3730 ABI sequencer.

Haplotype and Statistical Analysis {#s2_4}
----------------------------------

Two independent sample *t*-test and χ^2^ test were used to examine the clinical and demographic variables between responders and nonresponders. Genotype and allele frequency distributions were compared between the patients and controls and between the responders and nonresponders using the χ^2^ test for independence. The observed genotype frequencies were compared with the predicted frequencies to investigate the concordance with the Hardy--Weinberg (H-W) equilibrium. Logistic regression analysis was used to estimate the therapeutic effect associated with each genotype; odds ratios with 95% confidence intervals were obtained. A *p* \< 0.05 was considered to be statistically significant. The SHEsis online analysis software was used for linkage disequilibrium and haplotype analysis. Logistic regression analyses were performed using Statistical Package for the Social Sciences version 17.0 for Windows software (SPSS Inc., Chicago, IL). Adjustment for multiple comparisons was performed by Bonferroni correction.

Results {#s3}
=======

Comparison of General Data Between Control and Case Groups {#s3_1}
----------------------------------------------------------

A total of 208 cases in the control group, 101 males and 107 females, the average age was 31.71 ± 8.25 years. There were 292 patients in the study group, 143 males and 149 females; the average age was 30.89 ± 10.92 years. There was no significant difference in gender and age composition between the control group and the case group (χ^2^ = 0.008, *p* = 0.927; *t* = 0.954, *p* = 0.341), which was comparable.

Hardy--Weinberg Balance Analysis of *ABCB1* Gene Polymorphisms in the Control and Case Groups {#s3_2}
---------------------------------------------------------------------------------------------

Among the 208 control subjects, the theoretical number of genotypes was 81, the number of genotypes of CT was 98, and the number of genotypes of TT was 29. H-W analysis showed that there was no significant difference in the actual genotype distribution of rsl045642 SNP and the theoretical gene type distribution under H-W equilibrium, χ^2^ = 1.231, *p* = 0.267. According to this method, the H-W balance test was performed on the polymorphic loci rsl045642, rs2032583, rs2032582, rs2235040, rsl128503, and rs2235015 between the control group and the case group. As shown in [**Table 1**](#T1){ref-type="table"}, the six SNPs loci in the control and case groups all met the H-W balance. The population selected in this study is representative of the Han population and suitable for genetic analysis.

###### 

Equilibrium test of six single-nucleotide polymorphisms (SNPs) between the control group and the case group.

  SNP         Genotype   Controls (*n* = 208)   Cases (*n* = 292)                                      
  ----------- ---------- ---------------------- ------------------- ------ ------- ----- ----- ------- -------
  rs1045642   CC         85                     81                  1.23   0.267   103   109   2.27    0.132
  CT          90         98                     151                 139                                
  TT          33         29                     38                  44                                 
  rs2032583   CT         22                     21                  0.65   0.42    38    37    1.41    0.234
  TT          186        187                    254                 255                                
  rs2032582   GG         78                     72                  3.39   0.065   86    78    3.44    0.06
  GT          88         101                    130                 146                                
  TT          42         36                     76                  68                                 
  rs2235040   AG         22                     21                  0.65   0.42    40    38    1.58    0.21
  GG          186        187                    252                 254                                
  rs1128503   CC         39                     34                  1.8    0.18    40    35    1.97    0.161
  CT          91         100                    121                 132                                
  TT          78         73                     131                 126                                
  rs2235015   GG         187                    188                 0.59   0.44    254   255   1.414   0.23
  GT          21         20                     38                  37                                 

Comparison of Clinical Features Among the Responders and Nonresponders {#s3_3}
----------------------------------------------------------------------

Among the 292 patients included in this study, 39 patients dropped out because of adverse effects (*n* = 12), withdrawal of consent (*n* = 9), contrary to the scheme (*n* = 2), and lost to follow-up (*n* = 16); lastly, 253 patients completed the study. Clinical characteristics, use of drugs, and average drug doses between responders and nonresponders are shown in [**Table 2**](#T2){ref-type="table"}. No significant differences were found between the two groups according to the above indicators.

###### 

Clinical features, dosage, and drug among the responders and the nonresponders.

  -----------------------------------------------------------------------------------------------
                                               Nonresponders\    Responders\      F       *p*
                                               (*n* = 54)        (*n* = 199)              
  --------------------- ---------------------- ----------------- ---------------- ------- -------
  Age (years)                                  31.19 ± 10.124    30.78 ± 11.484   1.089   0.298

  Weight                                       60.778 ± 9.162    57.31 ± 9.3811   0.033   0.856

  Education                                    12.17 ± 3.994     11.93 ± 3.968    0.274   0.601

  Sex                   Male *n* (%)           27(50)            98(49.2)         0.012   0.912

  Female *n* (%)        27(50)                 101(50.8)                                  

  Marriage              Spinsterhood *n* (%)   29(53.7)          105(52.8)        2.441   0.119

  Married *n* (%)       21(38.9)               86(43.2)                                   

  Divorced *n* (%)      3(5.6)                 8(4.0)                                     

  Remarriage *n* (%)    1(1.9)                 0(0.0)                                     

  Drug                  Escitalopram *n* (%)   19(35.2)          67(33.7)         5.713   

  Paroxetine *n* (%)    6(11.1)                44(22.1)                                   

  Venlafaxine *n* (%)   19(35.2)               46(23.1)          0.222                    

  Duloxetine *n* (%)    7(13.0)                34(17.1)                                   

  Sertraline *n* (%)    3(5.6)                 8(4.0)                                     

  Doses                 Escitalopram           10.79 ± 2.507     10.67 ± 2.446    3.723   

  Paroxetine            21.67 ± 4.082          20.91 ± 2.908                              

  Venlafaxine           157.89 ± 23.648        158.15 ± 23.602   0.055                    

  Duloxetine            60.0 ± 0.00            60.0 ± 0.00                                

  Sertraline            58.33 ± 14.434         105.63 ± 52.470                            
  -----------------------------------------------------------------------------------------------

Genotype and Allele Frequencies in the Responders and Nonresponders {#s3_4}
-------------------------------------------------------------------

Genotype and allele distributions for the examined *ABCB1* gene SNPs in nonresponders and responders are shown in [**Table 3**](#T3){ref-type="table"}. The genotype and allelic distributions of rs1045642, rs2032582, rs2235040, rs1128503, and rs2235015 SNPs were not significantly different between nonresponders and responders. For rs2032583, genotype and allelic distributions significantly differed between the nonresponders and responders. The distribution of TT genotype and T allele frequency was higher in the responders than that in the nonresponders (*p* = 0.027, *p* = 0.033, respectively).

###### 

Genotype and allele frequencies of six SNPs of the ABCB1 gene in the nonresponders and the responders.

  ----------------------------------------------------------------------------------------------------------------------------------
  Genotype/allele   Responders\    Nonresponders\   **χ** ^2^   *p*       OR (95% CI)   Adjust OR (95% CI)           
                    (n = 199)(%)   (n = 54)(%)                                                                       
  ----------------- -------------- ---------------- ----------- --------- ------------- -------------------- ------- ---------------
  rs1045642                                                                                                          

  CC                73 (36.7)      21 (38.9)                              1                                  1       

  CT                97 (48.7)      26 (48.1)        0.136       0.934     1.073         0.560--2.056         1.159   0.575--2.336

  TT                29 (14.6)      7 (13.0)                               1.192         0.457--3.105         0.826   0.301--2.270

   C allele         243 (61.1)     68 (63.0)                              1                                  1       

   T allele         155 (38.9)     40 (37.0)        0.131       0.718     1.084         0.699--1.683         0.762   0.299--1.945

  rs2032583                                                                                                          

  TT                175 (87.9)     41 (75.9)                              1                                  1       

  CT                24 (12.1)      13 (24.1)        4.91        0.027\*   0.433\*       0.203--0.921         0.4\*   0.179--0.896

   T allele         374 (94.0)     95 (88.0)                              1                                  1       

   C allele         24 (6.0)       13 (12.0)        4.52        0.033\*   0.469\*       0.23--0.955          0.4\*   0.179--0.8966

  rs2032582                                                                                                          

  GG                63 (31.7)      16 (29.6)                              1                                  1       

  GT                81 (40.7)      25 (46.3)        0.574       0.751     0.823         0.405--1.671         0.878   0.41--1.877

  TT                55 (27.6)      13 (24.1)                              1.074         0.475--2.431         0.917   0.386--2.178

   G allele         207 (52.0)     57 (52.8)                              1                                  1       

   T allele         191 (48.0)     51 (47.2)        0.02        0.887     1.031         0.674--1.579         0.989   0.473--2.07

  rs2235040                                                                                                          

  AG                27 (13.6)      12 (22.2)                              1                                  1       

  GG                172 (86.4)     42 (77.8)        2.44        0.118     1.82          0.852--3.888         2.031   0.905--4.558

   A allele         27 (6.8)       12 (11.1)                              1                                  1       

   G allele         371 (93.2)     96 (88.9)        2.236       0.135     1.718         0.839--3.515         2.047   0.919--4.56

  rs1128503                                                                                                          

  CC                26 (13.1)      8 (14.8)                               1                                  1       

  CT                79 (39.7)      27 (50.0)        2.554       0.279     0.9           0.364--2.225         0.905   0.348--2.352

   C allele         131 (32.9)     43 (39.8)                              1                                  1       

   T allele         267 (67.1)     65 (60.2)        1.793       0.181     1.348         0.87--2.09           1.41    0.727--2.734

  rs2235015                                                                                                          

  GG                174 (87.4)     42 (77.8)                              1                                  1       

  GT                25 (12.6)      12 (22.2)        3.174       0.075     0.503         0.234--1.082         0.416   0.204--1.04

   G allele         373 (93.7)     96 (88.9)                              1                                  1       

   T allele         25 (6.3)       12 (11.1)        2.924       0.087     0.536         0.26--1.108          0.530   0.21--1.01
  ----------------------------------------------------------------------------------------------------------------------------------

\*Statistically significant difference between the groups (p \< 0.05).

CI, confidence interval; OR, odds ratio.

*ABCB1* Gene Polymorphism Loci and Clinical Response to Selective Serotonin Reuptake Inhibitors {#s3_5}
-----------------------------------------------------------------------------------------------

For SSRIs (sertraline, paroxetine, and escitalopram), no significant difference in genotype and allele frequency distribution was observed between the responders and nonresponders (*p* \> 0.05) ([**Table 4**](#T4){ref-type="table"}).

###### 

Genotype, allelic distribution of all genotyped single nucleotide polymorphisms among the treatment responders and nonresponders for selective serotonin reuptake inhibitor (SSRI) drugs group.

  --------------------------------------------------------------------------------------------------------------------------
              Responders\       Nonresponders (*n* = 28) (%)   χ^2^    *p*     OR (95% CI)            Adjust OR (95% CI)
              (*n* = 119) (%)                                                                         
  ----------- ----------------- ------------------------------ ------- ------- ---------------------- ----------------------
  rs1045642                                                                                           

  CC          42 (35.3)         9 (32.1)                                       1                      1

  CT          60 (50.4)         14 (50.0)                      0.259   0.879   0.918 (0.364--2.317)   0.717 (0.255--2.02)

  TT          17 (14.3)         5 (17.9)                                       0.729 (0.213--2.492)   0.389 (0.098--1.551)

   C allele   144 (60.5)        32 (57.1)                                      1                      1

   T allele   94 (39.5)         24 (42.9)                      0.213   0.644   0.87 (0.483--1.57)     0.479 (0.143--1.601)

  rs2032583                                                                                           

  TT          106 (89.1)        24 (85.7)                                      1                      1

  CT          13 (10.9)         4 (14.3)                       0.25    0.617   0.736 (0.221--2.455)   0.751 (0.205--2.747)

   T allele   225 (94.5)        52 (92.9)                                      1                      1

   C allele   13 (5.5)          4 (7.1)                        0.235   0.628   0.751 (0.235--2.397)   0.751 (0.205--2.747)

  rs2032582                                                                                           

  GG          38 (31.9)         5 (17.9)                                       1                      1

  GT          53 (44.5)         14 (50.0)                      2.352   0.309   0.498 (0.165--1.501)   0.336 (0.09--1.256)

  TT          28 (23.5)         9 (32.1)                                       0.409 (0.124--1.355)   0.237 (0.057--0.984)

   G allele   129 (54.2)        24 (42.9)                                      1                      1

   T allele   109 (45.8)        32 (57.1)                      2.338   0.126   0.634 (0.352--1.14)    0.509 (0.189--1.37)

  rs2235040                                                                                           

  AG          15 (12.6)         4 (14.3)                                       1                      1

  GG          104 (87.4)        24 (85.7)                      0.056   0.813   1.156 (0.352--3.794)   1.129 (0.316--4.032)

   A allele   15 (6.3)          4 (7.1)                                        1                      1

   G allele   223 (93.7)        52 (92.9)                      0.052   0.82    1.144 (0.364--3.588)   1.129 (0.316--4.032)

  rs1128503                                                                                           

  CC          16 (13.4)         2 (7.1)                                        1                      1

  CT          39 (32.8)         14 (50.0)                      3.124   0.21    0.348 (0.071--1.711)   0.303 (0.057--1.627)

  TT          64 (53.8)         12 (42.9)                                      0.667 (0.135--3.282)   0.483 (0.091--2.57)

   C allele   71 (29.8)         18 (32.1)                                      1                      1

   T allele   167 (70.2)        38 (67.9)                      0.115   0.735   1.114 (0.596--2.083)   1.224 (0.494--3.033)

  rs2235015                                                                                           

  GG          106 (89.1)        24 (85.7)                                      1                      1

  GT          13 (10.9)         4 (14.3)                       0.25    0.617   0.736 (0.221--2.455)   0.696 (0.191--2.543)

   G allele   225 (94.6)        52 (92.9)                                      1                      1

   T allele   13 (5.5)          4 (7.1)                        0.235   0.628   0.751 (0.235--2.397)   0.751 (0.235--2.397)
  --------------------------------------------------------------------------------------------------------------------------

The efficacy of SSRIs was examined for genotypes in the SSRI treatment group according to the HAM-D17 scores, decreased scores, and reducing score rate during the first, second, fourth, and sixth weeks. The HAM-D17 scores, decreased scores, and reducing score rate at the first, second, fourth, and sixth weeks were not significantly different among rs1045642, rs2032583, rs2032582, rs1128503, and rs2235015 (*p* \> 0.05). HAM-D17 decreased scores and reducing score rate did not reveal any significant difference with rs2235040 ([**Table 5**](#T5){ref-type="table"}); however, a significant difference was observed for the genotype of rs2235040 in the HAM-D17 scores (F = 4.349, *p* = 0.039) ([**Figure 1**](#f1){ref-type="fig"}).

###### 

Rs2235040 and response to antidepressants.

                                            1 week          2 weeks         4 weeks         6 weeks        F       p
  ------------------------- --------------- --------------- --------------- --------------- -------------- ------- -------
  Decreased score           AG (*n* = 19)   1.42 ± 1.71     5.47 ± 5.28     12.47 ± 5.78    17.42 ± 5.27   0.147   0.702
  GG (*n* = 128)            1.93 ± 2.49     5.74 ± 4.57     11.75 ± 5.99    15.82 ± 6.37                           
  Reducing score rate (%)   AG (*n* = 19)   5.31 ± 6.43     20.74 ± 18.96   47.36 ± 19.63   67.3 ± 17.42   0.323   0.571
  GG (*n* = 128)            8.38 ± 11.31    24.50 ± 19.09   49.64 ± 22.97   67.04 ± 23.77                          

![Hamilton Rating Scale for Depression (HAM-D) scores at the first, second, fourth, and sixth week.](fphar-10-00761-g001){#f1}

*ABCB1* Gene Polymorphism Loci and Clinical Response to Serotonin--Norepinephrine Reuptake Inhibitors {#s3_6}
-----------------------------------------------------------------------------------------------------

For SNRIs (venlafaxine and duloxetine), no significant difference was observed in the distribution of genotype and allele frequency of the rs1045642, rs2032582, rs2235040, rs1128503, and rs2235015 SNPs between the responders and nonresponders (*p* \> 0.05). For rs2032583, the T allele frequency and TT genotype were significantly increased in the responders compared with those in the nonresponders (*p* = 0.025 and *p* = 0.018, respectively) ([**Table 6**](#T6){ref-type="table"}).

###### 

Genotype, allelic distribution of all genotyped SNPs among the treatment responders and nonresponders for serotonin-norepinephrine reuptake inhibitors (SNRIs).

  -----------------------------------------------------------------------------------------------------------------
              Responders\      Nonresponders\   X^2^    *p*       OR (95% CI)              Adjust OR (95% CI)
              (*n* = 80) (%)   (*n* = 26) (%)                                              
  ----------- ---------------- ---------------- ------- --------- ------------------------ ------------------------
  rs1045642                                                                                

  CC          31 (38.8)        12 (46.2)                          1                        1

  CT          37 (46.3)        12 (46.2)        1.059   0.589     1.194 (0.47--3.03)       1.898 (0.644--5.593)

  TT          12 (15.0)        2 (7.7)                            2.323 (0.451--11.96)     1.499 (0.263--8.537)

   C allele   99 (61.9)        36 (69.2)                          1                        1

   T allele   61 (38.1)        16 (30.8)        0.918   0.338     1.386 (0.71--2.709)      1.11 (0.208--5.932)

  rS2032583                                                                                

  TT          69 (86.3)        17 (65.4)                          1                        1

  CT          11 (13.8)        9 (34.6)         5.581   0.018\*   0.301\* (0.108--0.842)   0.261\* (0.085--0.807)

   T allele   149 (93.1)       43 (82.7)                                                   1

   C allele   11 (6.9)         9 (17.3)         4.999   0.025\*   0.353\* (0.137--0.907)   0.261\* (0.085--0.807)

  rs2032582                                                                                

  GG          25 (31.3)        11 (42.3)                          1                        1

  GT          28 (35)          11 (42.3)        3.254   0.196     1.12 (0.414--3.028)      1.466 (0.473--4.541)

  TT          27 (33.8)        4 (15.4)                           2.97 (0.836--10.55)      2.502 (0.644--9.72)

   G allele   78 (48.75)       33 (63.5)                          1                        1

   T allele   82 (51.25)       19 (36.5)        3.405   0.065     1.826 (0.959--3.477)     2.07 (0.598--7.170)

  rs2235040                                                                                

  AG          12 (15)          8 (30.8)                           1                        1

  GG          68 (85)          18 (69.2)        3.188   0.074     2.519 (0.895--7.086)     2.98 (0.96--9.245)

   A allele   12 (7.5)         8 (15.4)                           1                        1

   G allele   148 (92.5)       44 (84.6)        2.856   0.091     2.242 (0.862--5.832)     2.98 (0.96--9.245)

  rs1128503                                                                                

  CC          10 (12.5)        6 (23.1)                           1                        1

  CT          40 (50.0)        13 (50.0)        2.083   0.353     1.846 (0.562--6.068)     1.838 (0.495--6.818)

  TT          30 (37.5)        7 (26.9)                           2.571 (0.698--9.476)     1.819 (0.422--7.839)

   C allele   60 (37.5)        25 (48.1)                          1                        1

   T allele   100 (62.5)       27 (51.9)        1.828   0.176     1.543 (0.821--2.901)     1.149 (0.385--3.43)

  rs2235015                                                                                

  GG          68 (85.0)        18 (69.2)                          1                        1

  GT          12 (15.0)        8 (30.8)         3.188   0.074     0.397 (0.141--1.117)     0.983 (0.944--1.024)

   G allele   148 (92.5)       44 (84.6)                          1                        1

   T allele   12 (7.5)         8 (15.4)         2.856   0.091     0.446 (0.171--1.16)      0.446 (0.171--1.16)
  -----------------------------------------------------------------------------------------------------------------

\*Statistically significant difference between the groups (p \< 0.05).

For SNRIs (venlafaxine and duloxetine), no significant difference was observed for the rs1045642, rs2032582, and rs1128503 SNPs in any of the HAM-D17 scores, decreased scores, and reducing score rate during the first, second, fourth, and sixth weeks (*p* \> 0.05). For rs2032583, the HAM-D17 scores of TT genotype are lower than those of the CT genotype, whereas the decreased scores and reducing score rate are higher than those of the CT genotype ([**Table 7**](#T7){ref-type="table"} and [**Figure 2**](#f2){ref-type="fig"}). The GG genotypes of rs2235040 have lower HAM-D17 scores than AG genotypes and higher decreased score and reducing score rate than AG genotypes ([**Table 8**](#T8){ref-type="table"} and [**Figure 3**](#f3){ref-type="fig"}). For rs2235015, the GG genotypes have lower HAM-D17 scores than those of the GT genotypes and higher in decreased score and reducing score rate than those of the GT genotypes ([**Table 9**](#T9){ref-type="table"} and [**Figure 4**](#f4){ref-type="fig"}).

###### 

Rs2032583 and response to antidepressants.

                                            1 week          2 weeks         4 weeks         6 weeks       F       *p*
  ------------------------- --------------- --------------- --------------- --------------- ------------- ------- ---------
  Decreased score           CT (*n* = 17)   1.40 ± 1.79     4.60 ± 4.11     10.3 ± 6.33     13.1 ± 6.51   5.949   0.016\*
  TT (*n* = 130)            2.23 ± 2.67     7.33 ± 4.62     12.86 ± 5.28    16.36 ± 5.29                          
  Reducing score rate (%)   CT (*n* = 17)   5.49 ± 7.33     18.69 ± 17.19   40.50 ± 24.09   51.4 ± 24.0   9.241   0.003\*
  TT (*n* = 130)            9.71 ± 11.76    31.29 ± 19.91   53.91 ± 20.80   68.8 ± 20.77                          

\*Statistically significant difference between the groups (p \< 0.05).

![HAM-D scores at the first, second, fourth, and sixth week (Rs2032583).](fphar-10-00761-g002){#f2}

###### 

Rs2235040 and response to antidepressants.

                                            1 week          2 weeks         4 weeks         6 weeks        F       *p*
  ------------------------- --------------- --------------- --------------- --------------- -------------- ------- ---------
  Decreased score           AG (*n* = 20)   1.45 ± 1.76     4.70 ± 4.07     10.75 ± 6.02    13.60 ± 6.06   4.288   0.041\*
  GG (*n* = 86)             2.22 ± 2.68     7.30 ± 4.64     12.76 ± 5.41    16.24 ± 5.47                           
  Reducing score rate (%)   AG (*n* = 20)   5.74 ± 7.21     19.19 ± 17.07   42.75 ± 23.17   53.9 ± 22.57   6.64    0.011\*
  GG (*n* = 86)             9.65 ± 11.80    31.18 ± 20.00   53.39 ± 21.33   68.22 ± 21.56                          

\*Statistically significant difference between the groups (p \< 0.05).

![HAM-D scores at the first, second, fourth, and sixth week (Rs2235040).](fphar-10-00761-g003){#f3}

###### 

Rs2235015 and response to antidepressants.

                                             1 week          2 weeks         4 weeks         6 weeks        F       *p*
  ------------------------- ---------------- --------------- --------------- --------------- -------------- ------- ---------
  Decreased score           GG (*n* = 130)   2.20 ± 2.67     7.30 ± 4.64     12.90 ± 5.28    16.23 ± 5.42   4.93    0.029\*
  GT (*n* = 17)             1.55 ± 1.85      4.70 ± 4.08     10.15 ± 6.25    13.65 ± 6.29                           
  Reducing score rate (%)   GG (*n* = 130)   9.53 ± 11.75    31.12 ± 20.0    53.96 ± 20.86   68.1 ± 21.32   7.151   0.009\*
  GT (*n* = 17)             6.27 ± 7.82      19.44 ± 17.28   40.31 ± 23.73   54.4 ± 23.90                           

\*Statistically significant difference between the groups (p \< 0.05).

![HAM-D scores at the first, second, fourth, and sixth week (Rs2235015).](fphar-10-00761-g004){#f4}

Discussion {#s4}
==========

We investigated the association among the six SNPs of the *ABCB1* gene and therapeutic response in the local Chinese Han population. Among the five SNPs, only one SNP (rs2032583) differed in genotype and allele frequencies between the responders and nonresponders. In particular, the TT genotype of this SNP was significantly more common in the responders than that in the nonresponders. This finding suggests that the C allele of rs2032583 may be a risk factor for MDD. In the SSRI therapy group, no correlation was found between the six SNPs of the *ABCB1*gene and therapeutic response to SSRIs (*p* \> 0.05). However, for the SNRI therapy group, only rs2032583 is associated with a therapeutic response to SNRIs in patients with MDD. The C allele of the *ABCB 1* gene SNP rs2032583 was negatively correlated with therapeutic response according to the logistic regression analyses. The genotype of *ABCB1* gene SNPs rs2235015 and rs2235040 were associated with decreased score and reducing score rate in the SNRIs therapy group, but because of the small sample size, there was no significant difference in the final effective and ineffective grouping. This finding indicated that *ABCB1* gene polymorphisms may not be associated with the treatment response to SSRIs, but with SNRIs. The TT genotype of the *ABCB1* gene SNP rs2032583 could be a predictive factor of improved treatment response to SNRIs. To our knowledge, this study is the first to report the genetic association of *ABCB1* gene polymorphism with therapeutic responses in a case-control design in Chinese Han people in Mainland China.

P-gp can restrict the entry of various substrates, such as antidepressants, from the bloodstream into the brain. Studies on *ABCB1* knockout animals have shown that *ABCB1*−/− mice possess higher intracerebral concentrations of escitalopram, trimipramine, amitriptyline, doxepin, venlafaxine, and paroxetine compared with those in wild-type mice ([@B16]; [@B15]; [@B14]). [@B4] reported a significant association of the nonsynonymous SNP *G2677T/A* (rs2032582) with treatment response to paroxetine in depressed patients. Moreover, the wild variant haplotype *3435C--2677G--1236T* is associated with poor response ([@B4]). In contrast, [@B8] found that depressed patients harboring the *2677 GG/GT* genotype responded to escitalopram treatment significantly better than patients with the *2677TT* genotype and suggested that this polymorphism could be used as genetic markers for predicting treatment response to escitalopram treatment in MDD (*n* = 15). [@B17] showed that polymorphisms in the *ABCB1* gene predict the response to antidepressant treatment in depressed patients (*n* = 133) receiving drugs that have been identified as substrates of P-gp (amitriptyline, paroxetine, venlafaxine, and escitalopram). However, [@B7] found that MDR1 variants *G2677T* (rs2032582) and *C3435T* (rs1045642) are not associated with therapeutic response to paroxetine in patients with MDD (*n* = 127). Furthermore, [@B9] did not find an association between *ABCB1C3435T*, *G2677T*, and *C1236T* polymorphisms and response and tolerance to citalopram in a large study sample (*n* = 831).

*ABCB1* gene polymorphism loci mutation might cause the variation of P-gp, thereby increasing drug concentrations in the brain to improve therapeutic effects. The specific function of rs2032583 (intron 22) is not clear. Clinical research has found the association between rs2032583 and antidepressant effects. The wild-type allele of rs2032583 is T and the mutant allele is C. The study by [@B11] showed that carriers of the C allele remitted faster than those with the TT genotype in the rs2032583 among paroxetine-treated patients and support the findings of [@B15] who found that rs2032583 genetic variants affected efficacy in patients of various ages treated with paroxetine and other *ABCB1* substrates ([@B17]; [@B11]). By contrast, the two previous results are inconsistent with our present results. For rs2032583, we found that TT genotype has lower HAM-D17 scores than those of CT genotype and higher in decreased score and reducing score rate than those of CT genotype. This finding suggested that the TT genotype of rs2032583 is likely to be a predictive factor of better treatment response to SNRIs.

Whether the locus mutation manipulates the coding region of P-protein conformation remains to be further basic research. The rs2032583 locus mutation might change the dimensional conformation of P-gp by allowing entry of drugs and toxic substances into the brain simultaneously to exacerbate the symptoms. In addition, the locus mutation changes P-gp conformation and then stops the SNRIs into the brain but does not affect SSRI substrate. Furthermore, locus mutation may not change the conformation of P-gp. The positive results of SNRIs may be attributed to the small sample size, thereby causing false-positive results in the study. Foreign studies may have different results because of various factors such as race, region, environment, and diet.

Several limitations of the present study should be acknowledged. First, we did not distinguish the first and recurrence of depressive patients joining the patients' group. Regression analysis determines the total course of the disease and whether they accepted treatment; however, previous treatment had some influence on the overall response rate. Hence, the present study can only obtain a trend about differences. Second, the present study only selected the drugs that have been identified as substrates of P-gp. Future studies should include no-P-gp substrates such as mirtazapine. Third, genetic effect is slight because of the small sample size. A large sample size is needed to improve the power of the test. Fourth, many receptors are involved to determine the effect of antidepressant drugs; hence, a combination of gene should be considered. Larger and more homogenous samples will be included in our future research to improve the statistical power. Because there may be a delayed response to symptom relief, 6 weeks of treatment may not be sufficient to fully demonstrate the relationship between *ABCB1* gene and clinical response, and we consider extending the duration of efficacy observation in future studies.
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